Zenith Drugs (NSE:ZENITHDRUG) Owner Earnings per Share (TTM): 0.16 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZENITHDRUG Zenith Drugs Ltd NSE:ZENITHDRUG
38 GF Score
Price ₹43.25
! 6 Warning Signs
View Full Analysis

What is Zenith Drugs Owner Earnings per Share (TTM)?

Zenith Drugs NSE:ZENITHDRUG -0.46% 38 Owner Earnings per Share (TTM) is 0.16 as of Mar. 2026. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 38/100. The stock has 6 warning signs investors should review. Among 463 Drug Manufacturers companies, Zenith Drugs ranks worse than 96.76% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Zenith Drugs does not have enough data to calculate Owner Earnings per Share (TTM), so as Price-to-Owner-Earnings ratio.


The historical rank and industry rank for Zenith Drugs's Owner Earnings per Share (TTM) or its related term are showing as below:

NSE:ZENITHDRUG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 240.43   Med: 268.99   Max: 315.74
Current: 295.37


During the past 6 years, the highest Price-to-Owner-Earnings ratio of Zenith Drugs was 315.74. The lowest was 240.43. And the median was 268.99.


NSE:ZENITHDRUG's Price-to-Owner-Earnings is ranked worse than
96.76% of 463 companies
in the Drug Manufacturers industry
Industry Median: 22.67 vs NSE:ZENITHDRUG: 295.37

Zenith Drugs's Earnings per Share (Diluted) for the six months ended in Mar. 2026 was ₹0.94. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2.30. It's PE Ratio (TTM) ratio for today is 18.81.

Zenith Drugs's EPS without NRI for the six months ended in Mar. 2026 was ₹0.94. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2.30. It's PE Ratio without NRI ratio for today is 18.81.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by FactSet. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Zenith Drugs Owner Earnings per Share (TTM) Related Terms


Zenith Drugs Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Zenith Drugs's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenith Drugs Owner Earnings per Share (TTM) Chart

Zenith Drugs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - - - 1.15

Zenith Drugs Semi-Annual Data
Mar24 Sep24 Mar25 Sep25 Mar26
Owner Earnings per Share (TTM) - - - - -

NSE:ZENITHDRUG vs ZTS: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Drugs's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenith Drugs Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zenith Drugs's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Zenith Drugs's Price-to-Owner-Earnings falls into.


NSE:ZENITHDRUG
38GF Score
Zenith Drugs Ltd NSE:ZENITHDRUG
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenith Drugs Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Zenith Drugs does not have enough data to calculate Owner Earnings per Share (TTM). Please check Wal-Mart Stores Inc, as your reference.

What does a Owner Earnings per Share (TTM) of 0.16 mean?
Zenith Drugs (NSE:ZENITHDRUG) has a Owner Earnings per Share (TTM) of 0.16 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Zenith Drugs. According to the industry distribution chart, Zenith Drugs ranks #448 out of 463 companies in the Drug Manufacturers industry, placing it in the top 96.8%.
Is Zenith Drugs' Owner Earnings per Share (TTM) too high?
Zenith Drugs' current Owner Earnings per Share (TTM) is 0.16. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 22.67. Zenith Drugs' value of 0.16 is 99.3% below this industry median. Based on the distribution chart, Zenith Drugs ranks #448 out of 463 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zenith Drugs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' Owner Earnings per Share (TTM) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zenith Drugs ranks #448 out of 463 companies for Owner Earnings per Share (TTM). This places Zenith Drugs in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 22.67. Zenith Drugs' value of 0.16 is 99.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 22.67, based on 463 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenith Drugs's current Owner Earnings per Share (TTM) of 0.16 is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Zenith Drugs. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 22.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenith Drugs's current Owner Earnings per Share (TTM) is 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current Owner Earnings per Share (TTM) of 0.16. The current Owner Earnings per Share (TTM) is 0.16 and 99.3% below the Drug Manufacturers industry median of 22.67. Zenith Drugs' overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current Owner Earnings per Share (TTM) is 0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenith Drugs Business Description

Address K. No. 72/5, Village Muradpura, Depalpur, Indore, MP, IND, 453001
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
38GF Score

Get the complete analysis for NSE:ZENITHDRUG

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹43.25
Price